Feasibility of a Medical-Legal Partnership Model to Connect Coal Miners QuitAid
Determining the Feasibility of Utilizing a Medical-Legal Partnership Model to Reach Coal Miners Who Use Tobacco and Nicotine Products and Connect Them to a Pharmacy-based Cessation Program
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
Background and rationale. Lung cancer rates are approximately 25% higher in Central Appalachia than in the rest of the U.S., and black-lung mortality has been markedly elevated in the region. Coal miners report the highest rates of cigarette smoking (about 23% vs. ~14% nationally) and smokeless tobacco use (about 23% vs. ~3% nationally) of any U.S. occupation, and TNP use magnifies the risk and severity of obstructive lung disease and lung cancer in this already high-risk group. National guidelines recommend that clinicians refer TNP users to cessation services via ask-advise-connect, but time constraints, limited provider buy-in, and patient factors limit adoption. In workers' compensation cases, claimants must prove their disease results from coal-dust exposure rather than TNP use, which creates both a health and a financial incentive for cessation and gives the miner-lawyer relationship unusual salience. This study leverages that relationship by having lawyers ask about TNP use (already routine at intake), advise quitting, and connect interested clients to a pharmacist-delivered cessation program (the novel component). QuitAid, previously developed and piloted by the study team, is a pharmacist-delivered MTM intervention designed to increase NRT adherence and promote cessation.
Aim 1 (implementation evaluation, lawyers). Guided by the Consolidated Framework for Implementation Research (CFIR), the team evaluates facilitators and barriers to adopting the ask-advise-connect model in approximately three black-lung law offices. Lawyers (up to 5 enrolled) complete baseline and follow-up surveys assessing self-efficacy, attitudes, and perceived facilitators/barriers, and participate in ~30-minute semi-structured telephone interviews (audio-recorded, analyzed thematically). Recruitment feasibility is measured by the proportion of coal miners referred per office and the number enrolled per month. Lawyers are study participants only, not investigators, and referral has no effect on a miner's legal case.
Aim 2 (randomized feasibility pilot, coal miners). Coal miners who use TNPs and have a current black-lung workers' compensation case with a participating law office are referred, screened, and consented by phone, complete a baseline assessment, and are then randomized 1:1 via computer-generated permuted-block randomization (generated in R, embedded in REDCap) to QuitAid (Yes vs. No). All participants receive 24 weeks of NRT beginning in Week 1 regardless of readiness to quit. Participants use of smoked TNPs (cigarettes, e-cigarettes, little cigars, cigarillos, cigars) receive the long-acting NRT patch; those using oral TNPs (smokeless tobacco, nicotine pouches) receive short-acting NRT gum; those using both receive the patch. Participants randomized to QuitAid who are ready to quit receive six telephonic pharmacist coaching sessions over 4 weeks; those not ready to quit receive up to three telephonic Pre-Quit Motivation Modules and may transition to QuitAid if they report readiness at any weekly check-in during Weeks 1-4. If readiness is not reported after four weekly check-ins, QuitAid ends. Follow-up assessments are conducted with all participants at 1, 2, 3, 4, 7, 11, 15, 19, and 26 weeks via secure REDCap links or telephone. Because this is a feasibility pilot, secondary clinical outcomes are analyzed descriptively and with logistic regression only to inform a future full-scale trial.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Dylan Allanson, MPH, RD
- Telefoonnummer: 4342430424
- E-mail: da4ac@virginia.edu
Studie Contact Back-up
- Naam: Ashley N DeMoss, MPH
- Telefoonnummer: (304) 574-8073
- E-mail: fzv3nn@virginia.edu
Studie Locaties
-
-
Virginia
-
Charlottesville, Virginia, Verenigde Staten, 22903
- University of Virginia
-
Onderonderzoeker:
- Roger T Anderson, PhD
-
Contact:
- Ashley N DeMoss, MPH
- Telefoonnummer: (304) 574-8073
- E-mail: fzv3nn@virginia.edu
-
Hoofdonderzoeker:
- Melissa A Little, PhD, MPH
-
Hoofdonderzoeker:
- Drew Harris, MD
-
Onderonderzoeker:
- Candace H Wood, PharmD
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Age ≥ 18 years
- Able to read, speak, and understand English
- A coal miner who uses tobacco and nicotine products, lives in the U.S., and has a current black-lung workers' compensation case with a participating law office
- Reports using tobacco and nicotine products daily for the past 6 months
- Willing and able to use NRT in the form of patch or gum
- Not pregnant or planning to become pregnant in the next 6 months
Exclusion Criteria:
- Medical contraindication to NRT (e.g., within the past 30 days: heart attack or stroke; within the past 6 months: serious or worsening angina, or very rapid or irregular heartbeat requiring medication)
- Pregnant or breastfeeding, or planning to become pregnant during the next 6 months
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: QuitAid + NRT
Participants receive the pharmacist-delivered QuitAid MTM program plus 24 weeks of NRT.
Those ready to quit receive six telephonic coaching sessions over 4 weeks; those not ready to quit receive up to three Pre-Quit Motivation Modules and may transition to QuitAid upon reporting readiness at a weekly check-in (Weeks 1-4).
|
Six telephonic pharmacist coaching sessions over 4 weeks focused on setting a quit date and quitting TNPs.
The first session (and subsequent proactive calls at ~days 2, 7, 14, 21, and 28) addresses negative beliefs about NRT, strengthens motivation and commitment to NRT use, monitors NRT use, provides feedback, and supports adherence.
Includes the Pre-Quit Motivation Modules (up to three telephonic sessions) for participants not yet ready to quit.
Andere namen:
24 weeks of NRT dispensed under a standing order and mailed to participants, with standard use guidelines.
Product is matched to TNP type: long-acting patch for smoked TNP users, short-acting gum for oral TNP users, patch for dual users.
|
|
Actieve vergelijker: NRT Only
Participants receive 24 weeks of NRT beginning in Week 1 without the QuitAid MTM program.
All follow-up assessments are conducted regardless of condition.
|
24 weeks of NRT dispensed under a standing order and mailed to participants, with standard use guidelines.
Product is matched to TNP type: long-acting patch for smoked TNP users, short-acting gum for oral TNP users, patch for dual users.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Feasibility of Randomization
Tijdsspanne: Through study recruitment (approximately 6 months)
|
Number of coal miners who need to be approached and screened in order to randomize 100 TNP users.
|
Through study recruitment (approximately 6 months)
|
|
Retention
Tijdsspanne: 26 weeks
|
Proportion of randomized coal miners who complete the 26-week follow-up visit.
|
26 weeks
|
|
Fidelity of Implementation
Tijdsspanne: Through the 4-week intervention period
|
Fidelity of QuitAid delivery, assessed as adherence to QuitAid, quality of program delivery, participant responsiveness, and program differentiation, captured via a session checklist and self-reported end-of-session reflections.
|
Through the 4-week intervention period
|
|
Dose of the Medication Therapy Management (MTM) Intervention
Tijdsspanne: Through the 4-week intervention period
|
Number of MTM (QuitAid) sessions received per participant, documented in the REDCap database.
|
Through the 4-week intervention period
|
|
Dose of NRT
Tijdsspanne: Baseline through 26 weeks
|
Reported proportion of provided NRT that was used by participants.
|
Baseline through 26 weeks
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Self-Reported Tobacco Abstinence
Tijdsspanne: 1, 2, 3, 4, 7, 11, 15, 19, and 26 weeks
|
Self-reported abstinence, defined as no use of any tobacco or nicotine products within the past 7 days.
|
1, 2, 3, 4, 7, 11, 15, 19, and 26 weeks
|
|
Quit Attempts
Tijdsspanne: Baseline through 26 weeks
|
Number of quit attempts since the previous contact, where a quit attempt is abstinence for ≥24 hours not due to involuntary or forced cessation (e.g., hospitalization).
|
Baseline through 26 weeks
|
|
Frequency of Urges to Use TNPs
Tijdsspanne: Baseline through 26 weeks
|
Self-reported frequency of urges to use tobacco/nicotine products.
|
Baseline through 26 weeks
|
|
Adherence to Assigned Treatment(s)
Tijdsspanne: Baseline through 26 weeks
|
Percentage of intervention sessions completed and percentage of provided NRT used.
|
Baseline through 26 weeks
|
|
Adherence to NRT
Tijdsspanne: Baseline through 26 weeks
|
Adherence to NRT (patch or gum), measured as the percentage of provided NRT used.
|
Baseline through 26 weeks
|
|
Strength of urges to use TNPs
Tijdsspanne: Baseline through 26 weeks
|
Self-reported strength of urges to use tobacco/nicotine products.
|
Baseline through 26 weeks
|
Andere uitkomstmaten
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Program satisfaction
Tijdsspanne: 26 weeks
|
Participant-reported barriers to treatment utilization, satisfaction with treatment components, and suggestions for improvement, with items focused on perceived capacity and opportunity to engage with the interventions.
|
26 weeks
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Melissa A Little, PhD, MPH, University of Virginia
- Hoofdonderzoeker: Drew Harris, MD, University of Virginia
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Psychische aandoening
- Ziekten van de luchtwegen
- Longziekten
- Middelgerelateerde aandoeningen
- Chemisch veroorzaakte aandoeningen
- Longziekten, interstitieel
- Longletsel
- Pneumoconiose
- Gedrag
- Gezondheidsgedrag
- Tabaksgebruiksstoornis
- Stoppen met roken
- Stoppen met tabaksgebruik
- Anthracose
- Health Services Administration
- Therapeutica
- Drugstherapie
- Gezondheidsdiensten
- Gezondheidszorgfaciliteiten personeel en diensten
- Gezondheidszorg economie en organisaties
- Management voor patiëntenzorg
- Financiering, georganiseerd
- Economie
- Farmaceutische Diensten
- Medicare Deel D
- Verzekering, Farmaceutische Diensten
- Verzekering, Gezondheid
- Verzekering
- Medicare
- Nicotine -vervangingstherapie
- Medicatie Therapie Beheer
Andere studie-ID-nummers
Andere studie-ID-nummers
- HSR 303071
- 5P30CA044579-30 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .